Designing Longevity
Skip to main content
Emerging ResearchPeptide

MOTS-c

The exercise mimetic

Mitochondrial-Derived Peptide

Last updated: August 2026
Share:

Evidence Level: Emerging Research

Very new, early-stage research, high uncertainty

Regulatory Status: Not approved anywhere. Placed in FDA 503A Category 2 in 2023. On July 23, 2026 an FDA advisory committee voted 7 to 5, with two abstentions, to recommend adding it to the permitted 503A list; that vote is advisory and non-binding.

MOTS-c is a 16-amino-acid peptide encoded not by your nuclear DNA but by your , which is unusual and genuinely important biology. Your body releases it during exercise, and it activates , the same energy-sensing pathway exercise and metformin act on. It is sold as an "exercise mimetic." No human trial has tested it as a treatment for anything.

How It Works

MOTS-c is one of the more scientifically interesting compounds in this catalog, which makes the evidence gap more frustrating rather than less.

The genome writes proteins. carry their own small circle of DNA, a leftover from when they were free-living bacteria. For decades that DNA was thought to encode only components of the energy-production machinery. Then researchers found short peptides encoded inside those genes that get released into the bloodstream and act as hormones on distant tissues. MOTS-c, encoded inside the 12S ribosomal RNA gene, was among the first identified.

That means your are not just power plants. They are endocrine organs sending signals about your metabolic state to the rest of your body. That is a real and important discovery.

What MOTS-c does. It activates , the cellular fuel gauge that switches on when energy runs low. AMPK activation shifts cells toward burning fuel rather than storing it, increases glucose uptake, and triggers cellular cleanup processes. It is the pathway exercise activates, and the pathway metformin acts on. In mice, MOTS-c improved insulin sensitivity and protected against diet-induced obesity.

The exercise connection is documented in humans. A 2021 Nature Communications study showed MOTS-c is released during exercise in both mice and humans, and linked it to age-dependent physical decline and muscle homeostasis. That is real human data, and it is why the "exercise mimetic" framing exists.

Read that carefully, though. Showing that your body produces more MOTS-c when you exercise is a completely different claim from showing that injecting MOTS-c produces the benefits of exercise. The first is established. The second has never been tested in a human.

This distinction is the entire gap between the science and the sales pitch. Every legitimate MOTS-c finding is about MOTS-c as a signal your body generates. Every commercial claim is about MOTS-c as a drug you inject. Nobody has bridged them.

MOTS-c levels also decline with age, and lower levels correlate with worse metabolic health. That is a correlation, and the direction of causation is genuinely unclear: less exercise produces less MOTS-c and worse metabolic health, so MOTS-c may be a marker of the exercise you are not doing rather than a cause of anything.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Longevity biomarkersModerate certainty

MOTS-c is released into circulation during exercise in humans.

Population: Humans and mice undergoing exercise

Why this rating

Directly measured in humans and published in Nature Communications, with a consistent mechanistic story linking MOTS-c to muscle homeostasis and age-related decline. This is a well-supported observation about human physiology. Note carefully what it does and does not establish: it says your body makes this peptide during exercise, not that taking it produces any benefit.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Glycemic controlPreclinical certainty

Administering MOTS-c improves insulin sensitivity, body composition, or metabolic health.

Population: No human population has been studied. Evidence is from mice.

Why this rating

The mouse evidence is strong and published in a top-tier journal: MOTS-c improved insulin sensitivity and prevented diet-induced obesity. No human trial has administered MOTS-c and measured any metabolic outcome. There is also no published human pharmacokinetic data, so the basic question of whether an injected dose reaches target tissue at an active concentration is unanswered.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • Backed by legitimate, well-published biology in high-quality journals including Cell Metabolism and Nature Communications
  • Human data confirms MOTS-c is released during exercise, linking it to a real physiological process
  • Activates , a well-validated metabolic target shared with exercise and metformin
  • Improved insulin sensitivity and protected against diet-induced obesity in mouse models
  • Declining MOTS-c levels with age correlate with worse metabolic health
  • An FDA advisory committee voted in July 2026 to recommend it for the permitted compounding list

Risks & Considerations

  • No human clinical trial has tested injected MOTS-c as a treatment for any condition
  • The human data shows your body makes MOTS-c during exercise, which is not evidence that injecting it does anything
  • No published human pharmacokinetic data, so nobody knows what dose reaches what tissue
  • MOTS-c effects appear to vary with DNA background, meaning results may differ substantially between people
  • Unregulated supply with no verified identity or purity
  • Real exercise produces MOTS-c along with dozens of other adaptations, and no injection reproduces that
  • Marketed with specific metabolic claims that have no human trial support

Dosing Information

There is no established human dose, because no human dose-finding study has been conducted. The figures circulating come from extrapolated mouse dosing.

  • •Community protocols commonly suggest 5 to 10mg subcutaneously, two or three times per week
  • •Those figures are extrapolated from rodent dosing and have no human pharmacokinetic basis
  • •Cycles of 4 to 8 weeks are conventional in clinic practice rather than evidence-based
  • •No published data on absorption, half-life, or tissue distribution in humans
  • •We are not publishing a protocol for a compound with no human trial data

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1The intervention that reliably raises your MOTS-c is exercise, and it is free
  • 2If your goal is activation with human evidence, metformin has decades of human data and ongoing longevity trials
  • 3Track objective markers if you try it: fasting glucose, fasting insulin, HbA1c. Subjective energy is not a useful endpoint
  • 4Be precise when reading MOTS-c claims. "Released during exercise" and "reproduces exercise" are different sentences
  • 5Watch the FDA rulemaking following the July 2026 advisory vote if supply quality matters to you

Key Research

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Cell Metabolism, 2015

The landmark paper identifying MOTS-c. In mice, it targeted skeletal muscle, activated AMPK, improved insulin sensitivity, and prevented diet-induced obesity.

View Study

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Nature Communications, 2021

MOTS-c is released during exercise in both mice and humans, and regulates muscle homeostasis and age-related physical decline.

View Study

FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

FDA advisory committee proceedings, 2026

The committee voted 7 to 5, with two abstentions, to recommend MOTS-c for the 503A bulk drug substances list. The vote is advisory and does not change its legal status without FDA rulemaking.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has very early human evidence.

Frequently Asked Questions

Is MOTS-c really an exercise mimetic?

It is a peptide your body releases when you exercise, and that has been measured in humans. Whether injecting it reproduces the benefits of exercise is a different question, and nobody has tested it. The "exercise mimetic" label describes a hypothesis about what it might do, not a demonstrated result. Exercise triggers dozens of adaptations simultaneously; MOTS-c is one signal among many.

Are there human trials of MOTS-c?

There is real human data showing MOTS-c is released during exercise and that levels decline with age. There are no human trials administering MOTS-c as a treatment and measuring an outcome. That distinction is the entire gap between the published science, which is genuinely good, and the commercial claims, which have nothing behind them.

What does MOTS-c do?

It activates , your cells' energy-sensing switch, which shifts metabolism toward burning fuel rather than storing it and triggers cellular cleanup processes. It is encoded inside your DNA rather than your nuclear DNA, which was a surprising discovery: it means mitochondria act as endocrine organs sending signals throughout the body, not just as power plants.

Is MOTS-c legal?

It is not approved anywhere. The FDA placed it in of the bulk substances list in 2023. On July 23, 2026 an FDA advisory committee voted 7 to 5, with two abstentions, to recommend adding it to the permitted 503A list. That vote is advisory and non-binding, and changing its status requires FDA rulemaking that typically takes 12 to 24 months.

How is MOTS-c different from humanin?

Both are -derived peptides, meaning both are encoded in mitochondrial DNA and act as signaling molecules. MOTS-c is metabolic, working through on muscle and fat. Humanin is primarily neuroprotective and cytoprotective. They belong to the same newly discovered family and do quite different jobs, and neither has been tested as a treatment in humans.

Does MOTS-c work the same for everyone?

Probably not, and this is one of the more interesting caveats. Research has found that MOTS-c effects vary with DNA background, which differs between populations. That means the response to MOTS-c may be genuinely different from person to person in ways that are not yet characterized, which is another reason human trials matter.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Slow Aging GuideThe Energy GuideThe Weight Loss Guide

Related Peptides

HumaninMitochondrial-Derived Peptide
SS-31 (Elamipretide)Mitochondria-Targeting Tetrapeptide
EpithalonPineal Tetrapeptide

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: